Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • ASN Meeting Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
    • Reprint Information
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Reprint Information
    • Subscriptions
    • Feedback
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

Can We Save the Kidneys by Protecting the Heart?

Srisakul Chirakarnjanakorn and W.H. Wilson Tang
CJASN February 2015, 10 (2) 165-166; DOI: https://doi.org/10.2215/CJN.12761214
Srisakul Chirakarnjanakorn
*Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio; and
†Division of Cardiology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
W.H. Wilson Tang
*Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • cardiovascular disease
  • heart failure
  • renal dysfunction

It is of utmost importance to improve detection at an early stage of disease to prevent the development of overt disease. Over the past several decades, we have gained significant pathophysiologic insights into specific disease processes using a combination of circulating biomarkers of subclinical abnormalities and risk prediction models. From a cardiac standpoint, two clinically available biomarkers have emerged, because they are specifically released from cardiac myocytes in response to myocardial stress and injury. As biomarkers of myocardial stress, B-type natriuretic peptide (BNP) and the inactive amino terminus of its prohormone (NT-proBNP) are synthesized mainly from the ventricles in response to pressure and/or volume overload. Hence, increased BNP production signals the counter-regulatory responses to adverse neurohormonal effects on the cardiovascular system. Beyond their intended cardiovascular diagnostic uses in heart failure, natriuretic peptides have been shown to provide consistent risk stratification across the spectrum of cardiovascular diseases (1) and in the general population (2). Meanwhile, cardiac troponins (cTns) are intracellular structural proteins involved in regulation of contraction and relaxation of cardiomyocytes. Detection of circulating cTn levels represents an indicator of myocardial injury. However, low levels of circulating cTn have been detected in heart failure as well as other conditions indicative of subclinical myonecrosis (3), and they may portend adverse consequences in the nonacute setting (4). The availability of highly sensitive assays of cTn with a detection limit that is 10-fold lower than conventional assays has further expanded the ability of cTn to risk stratify. For example, detectable circulating cTn was found in 25% of the general population with low to moderate cardiovascular risk (5) and 66% in the Cardiovascular Health Study with participants who are elderly and without heart failure (6). Levels of circulating cTn have a graded association with subclinical cardiac abnormalities, such as left ventricular mass, left ventricular ejection fraction, coronary artery calcium score, and CKD (5). Furthermore, detectable cTn has been independently associated with all-cause mortality, cardiovascular mortality, and incident heart failure (5–7).

The study by Bansal et al. (8) published in this issue of CJASN extends the risk prediction use of NT-proBNP and cTn measured by a highly sensitive assay for the decline in kidney function in an elderly population at risk of developing progressive CKD. Not surprisingly, participants with higher NT-proBNP and cTn were older and had more cardiovascular comorbidities and/or pathology as well as lower eGFR. However, after extensive adjustments for cardiac and renal factors, both biomarkers had a significantly graded association with decline in kidney function and incident CKD over the median follow-up of 6 years (8). Bansal et al. (8) provided extensive statistical demonstrations to solidify their hypothesis that subclinical myocardial dysfunction as detected by these sensitive cardiac-specific biomarkers may serve as an indicator of heightened risk for adverse kidney outcomes in a nonheart failure population.

The burning question becomes as follows: can protecting the vulnerable heart save the kidneys? Whether these observed associations can support the evolving concept of cardiorenal syndrome (the complex pathophysiologic interconnections between cardiac and renal dysfunctions) remains to be determined. Nevertheless, both disease processes share common pathophysiologic feedback pathways, including activation of the renin-angiotensin-aldosterone and adrenergic systems leading to inflammation, oxidative stress, and endothelial dysfunction. Hence, this is an attractive concept, with a dysfunctional heart driving a vicious cycle leading to further damage and dysfunction of both the heart and the kidneys. It is also important to point out that both NT-proBNP and cTn are primarily cleared by the kidneys, because they are frequently elevated in patients with CKD and inversely correlated with eGFR (9,10). Furthermore, both biomarkers were independently and strongly associated with mortality, cardiovascular events, and incident heart failure in the CKD population, even after adjusting for demographic variables, traditional cardiovascular risks, and indices of kidney disease (11,12). Therefore, it is conceivable that, as an alternative explanation, elevated cardiac biomarkers may represent a more sensitive measure of underlying renal insufficiency (potentially beyond mechanisms detectable by cystatin C), thereby independently associating with subsequent kidney function decline. Regardless of the mechanisms of their accumulation, elevated cardiac biomarkers portend poor prognosis likely with or without progressive renal dysfunction.

How do these results translate into clinical practice? First, it is important to recognize that the end points used in this study were not hard end points (e.g., incident development of ESRD or mortality associated with renal diseases) but surrogate measures of kidney function decline on the basis of changes in eGFR that were arbitrarily defined (8). Therefore, routine assessment of these cardiac biomarkers to guide therapy with the intention to alter the natural history of CKD remains unproven. Regardless of the renal consequences, it is still important to recognize (although beyond the findings of this paper) that detecting elevated cardiac biomarkers represents a valuable opportunity to investigate and intervene on potential underlying cardiac vulnerabilities in patients with CKD, whereas the lack of such biomarker elevations can be prognostically reassuring (8). Second, the key to achieving meaningful use of such clinical biomarkers demands the ability for their levels to indicate a change in therapeutic approaches. Indeed, there have been promising data to support the use of cardioprotective drug regimens, such as angiotensin-converting enzyme inhibitors and β-adrenergic blockers, for delaying progression of cardiac dysfunction in the setting of elevated BNP levels in the general practice setting (13) as well as the setting of elevated cTn in patients receiving high-dose chemotherapy (14). It may, therefore, be prudent to explore future interventional studies that use cardiac biomarkers to better define indications for guideline-directed medical therapy that are not routinely used in the CKD population (e.g., β-blockers) in the prevention of heart failure and cardiovascular diseases above the reliance of cardiac imaging information and beyond the concept of renoprotection. After all, heart disease remains the major cause of death for patients with CKD; thus, protecting the heart may even save more than the kidneys.

Disclosures

None.

Acknowledgments

This work is funded, in part, by National Institutes of Health Grant R01-HL103931.

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related article, “NT-ProBNP and Troponin T and Risk of Rapid Kidney Function Decline and Incident CKD in Elderly Adults,” on pages 205–214.

  • Copyright © 2015 by the American Society of Nephrology

References

  1. 1.↵
    1. Tang WH,
    2. Francis GS,
    3. Morrow DA,
    4. Newby LK,
    5. Cannon CP,
    6. Jesse RL,
    7. Storrow AB,
    8. Christenson RH,
    9. Apple FS,
    10. Ravkilde J,
    11. Wu AH
    ; National Academy of Clinical Biochemistry Laboratory Medicine: National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 116: e99–e109, 2007
    OpenUrlFREE Full Text
  2. 2.↵
    1. McKie PM,
    2. Rodeheffer RJ,
    3. Cataliotti A,
    4. Martin FL,
    5. Urban LH,
    6. Mahoney DW,
    7. Jacobsen SJ,
    8. Redfield MM,
    9. Burnett JC Jr..
    : Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: Biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 47: 874–880, 2006
    OpenUrlCrossRef
  3. 3.↵
    1. Francis GS,
    2. Tang WH
    : Cardiac troponins in renal insufficiency and other non-ischemic cardiac conditions. Prog Cardiovasc Dis 47: 196–206, 2004
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Tang WH,
    2. Wu Y,
    3. Nicholls SJ,
    4. Brennan DM,
    5. Pepoy M,
    6. Mann S,
    7. Pratt A,
    8. Van Lente F,
    9. Hazen SL
    : Subclinical myocardial necrosis and cardiovascular risk in stable patients undergoing elective cardiac evaluation. Arterioscler Thromb Vasc Biol 30: 634–640, 2010
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. de Lemos JA,
    2. Drazner MH,
    3. Omland T,
    4. Ayers CR,
    5. Khera A,
    6. Rohatgi A,
    7. Hashim I,
    8. Berry JD,
    9. Das SR,
    10. Morrow DA,
    11. McGuire DK
    : Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 304: 2503–2512, 2010
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. deFilippi CR,
    2. de Lemos JA,
    3. Christenson RH,
    4. Gottdiener JS,
    5. Kop WJ,
    6. Zhan M,
    7. Seliger SL
    : Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 304: 2494–2502, 2010
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Grodin JL,
    2. Neale S,
    3. Wu Y,
    4. Hazen SL,
    5. Tang WH
    : Prognostic comparison of different sensitivity cardiac troponin assays in stable heart failure [published online ahead of print October 15, 2014]. Am J Med doi:10.1016/j.amjmed.2014.09.029
  8. 8.↵
    1. Bansal N,
    2. Katz R,
    3. Dalrymple L,
    4. de Boer I,
    5. DeFilippi C,
    6. Kestenbaum B,
    7. Park M,
    8. Sarnak M,
    9. Seliger S,
    10. Shipak M
    : N-terminal pro–B-type natriuretic peptide, troponin T, and risk of rapid kidney function decline and incident CKD in elderly adults: The Cardiovascular Health Study. Clin J Am Soc Nephrol 10: 205–214, 2015
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Tagore R,
    2. Ling LH,
    3. Yang H,
    4. Daw HY,
    5. Chan YH,
    6. Sethi SK
    : Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol 3: 1644–1651, 2008
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Vickery S,
    2. Price CP,
    3. John RI,
    4. Abbas NA,
    5. Webb MC,
    6. Kempson ME,
    7. Lamb EJ
    : B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: Relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 46: 610–620, 2005
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Bansal N,
    2. Hyre Anderson A,
    3. Yang W,
    4. Christenson RH,
    5. deFilippi CR,
    6. Deo R,
    7. Dries DL,
    8. Go AS,
    9. He J,
    10. Kusek JW,
    11. Lash JP,
    12. Raj D,
    13. Rosas S,
    14. Wolf M,
    15. Zhang X,
    16. Shlipak MG,
    17. Feldman HI
    : High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study [published online ahead of print October 2, 2014]. J Am Soc Nephrol doi:ASN.2014010108
  12. 12.↵
    1. Scheven L,
    2. de Jong PE,
    3. Hillege HL,
    4. Lambers Heerspink HJ,
    5. van Pelt LJ,
    6. Kootstra JE,
    7. Bakker SJ,
    8. Gansevoort RT
    ; PREVEND study group: High-sensitive troponin T and N-terminal pro-B type natriuretic peptide are associated with cardiovascular events despite the cross-sectional association with albuminuria and glomerular filtration rate. Eur Heart J 33: 2272–2281, 2012
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Ledwidge M,
    2. Gallagher J,
    3. Conlon C,
    4. Tallon E,
    5. O’Connell E,
    6. Dawkins I,
    7. Watson C,
    8. O’Hanlon R,
    9. Bermingham M,
    10. Patle A,
    11. Badabhagni MR,
    12. Murtagh G,
    13. Voon V,
    14. Tilson L,
    15. Barry M,
    16. McDonald L,
    17. Maurer B,
    18. McDonald K
    : Natriuretic peptide-based screening and collaborative care for heart failure: The STOP-HF randomized trial. JAMA 310: 66–74, 2013
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Cardinale D,
    2. Colombo A,
    3. Sandri MT,
    4. Lamantia G,
    5. Colombo N,
    6. Civelli M,
    7. Martinelli G,
    8. Veglia F,
    9. Fiorentini C,
    10. Cipolla CM
    : Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114: 2474–2481, 2006
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 10 (2)
Clinical Journal of the American Society of Nephrology
Vol. 10, Issue 2
February 06, 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Can We Save the Kidneys by Protecting the Heart?
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Can We Save the Kidneys by Protecting the Heart?
Srisakul Chirakarnjanakorn, W.H. Wilson Tang
CJASN Feb 2015, 10 (2) 165-166; DOI: 10.2215/CJN.12761214

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Can We Save the Kidneys by Protecting the Heart?
Srisakul Chirakarnjanakorn, W.H. Wilson Tang
CJASN Feb 2015, 10 (2) 165-166; DOI: 10.2215/CJN.12761214
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Steroid Regimen for Children with Nephrotic Syndrome Relapse
  • Mind the Gap
  • Opportunities for Improvement in Quality of Care of PD-Related Peritonitis in Children
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • NT-ProBNP and Troponin T and Risk of Rapid Kidney Function Decline and Incident CKD in Elderly Adults
  • PubMed
  • Google Scholar

Keywords

  • cardiovascular disease
  • heart failure
  • renal dysfunction

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe

© 2021 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire